BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 17367974)

  • 1. Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol.
    Zizka J; Klzo L; Ferda J; Mrklovský M; Bukac J
    Eur J Radiol; 2007 May; 62(2):186-91. PubMed ID: 17367974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normal dynamic MRI enhancement patterns of the upper abdominal organs: gadoxetic acid compared with gadobutrol.
    Kühn JP; Hegenscheid K; Siegmund W; Froehlich CP; Hosten N; Puls R
    AJR Am J Roentgenol; 2009 Nov; 193(5):1318-23. PubMed ID: 19843748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fat-suppressed dynamic and delayed gadolinium-enhanced volumetric interpolated breath-hold magnetic resonance imaging of cholangiocarcinoma.
    Leyendecker JR; Gakhal M; Elsayes KM; McDermott R; Narra VR; Brown JJ
    J Comput Assist Tomogr; 2008; 32(2):178-84. PubMed ID: 18379298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA.
    Tamada T; Ito K; Sone T; Yamamoto A; Yoshida K; Kakuba K; Tanimoto D; Higashi H; Yamashita T
    J Magn Reson Imaging; 2009 Mar; 29(3):636-40. PubMed ID: 19243060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.
    Filippone A; Blakeborough A; Breuer J; Grazioli L; Gschwend S; Hammerstingl R; Heinz-Peer G; Kittner T; Laghi A; Leen E; Lencioni R; Lucidarme O; Remplik P; Robinson PJ; Ruehm SG; Schaefer F; Stoupis C; Tombach B; Valette PJ; Zech CJ; Huppertz A
    J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
    Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
    Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body MRI with assessment of hepatic and extraabdominal enhancement after administration of gadoxetic acid for staging of rectal carcinoma.
    Huppertz A; Franiel T; Wagner M; Püttcher O; Wagner J; Rief M; Schwenke C; Hamm B; Strassburg J
    Acta Radiol; 2010 Oct; 51(8):842-50. PubMed ID: 20698804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
    Feuerlein S; Gupta RT; Boll DT; Merkle EM
    Eur J Radiol; 2012 Sep; 81(9):2037-41. PubMed ID: 21719224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two different injection rates of gadoxetic acid for arterial phase MRI of the liver.
    Chung SH; Kim MJ; Choi JY; Hong HS
    J Magn Reson Imaging; 2010 Feb; 31(2):365-72. PubMed ID: 20099350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
    Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
    Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast material for abdominal dynamic contrast-enhanced 3D MR angiography with parallel imaging: intraindividual equimolar comparison of a macrocyclic 1.0 M gadolinium chelate and a linear ionic 0.5 M gadolinium chelate.
    Hadizadeh DR; Von Falkenhausen M; Kukuk GM; Schöneseiffen K; Gieseke J; Schild HH; Willinek WA
    AJR Am J Roentgenol; 2010 Mar; 194(3):821-9. PubMed ID: 20173166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study].
    Vogl TJ; Friebe CE; Balzer T; Mack MG; Steiner S; Schedel H; Pegios W; Lanksch W; Banzer D; Felix R
    Radiologe; 1995 Aug; 35(8):508-16. PubMed ID: 7568795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of liver and pancreas on late hepatic arterial phase imaging: quantitative comparison among multiple gadolinium-based contrast agents at 1.5 Tesla MRI.
    Kim MJ; Kim SH; Kim HJ; Kim BS; Hernandes M; Semelka RC
    J Magn Reson Imaging; 2013 Jul; 38(1):102-8. PubMed ID: 23677890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
    Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
    Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproducibility of the aortic input function (AIF) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the kidneys in a volunteer study.
    Mendichovszky IA; Cutajar M; Gordon I
    Eur J Radiol; 2009 Sep; 71(3):576-81. PubMed ID: 19004588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAIPIRINHA-Dixon-TWIST (CDT)-volume-interpolated breath-hold examination (VIBE) for dynamic liver imaging: comparison of gadoterate meglumine, gadobutrol and gadoxetic acid.
    Budjan J; Ong M; Riffel P; Morelli JN; Michaely HJ; Schoenberg SO; Haneder S
    Eur J Radiol; 2014 Nov; 83(11):2007-12. PubMed ID: 25172427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 Tesla.
    Giesel FL; Mehndiratta A; Risse F; Rius M; Zechmann CM; von Tengg-Kobligk H; Gerigk L; Kauczor HU; Politi M; Essig M; Griffiths PD; Wilkinson ID
    Acta Radiol; 2009 Jun; 50(5):521-30. PubMed ID: 19337867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does injection flow rate have an impact on arterial phase image degradation in liver MRI? A comparison of gadoxetic acid versus gadobutrol.
    Cohen-Hallaleh V; Guo L; Hosseini-Nik H; Razaghi Kashani N; Menezes R; Jhaveri K
    Clin Radiol; 2017 Nov; 72(11):994.e1-994.e8. PubMed ID: 28673445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
    Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
    Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.